ArticleRheumatology (Oxford, England)2021
All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study.
Article in Rheumatology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Nursing interventions for people with systemic lupus erythematosus: a systematic review.Lupus science & medicine · 2026Pooled it
- Mortality and survival in patients with systemic lupus erythematosus in the Middle East and North Africa: a systematic review and meta-analysis.Rheumatology international · 2026Pooled it
- The vascular endothelial growth factor as a candidate biomarker of systemic lupus erythematosus: a GRADE-assessed systematic review and meta-analysis.Clinical and experimental medicine · 2024Pooled it
- Risk of diabetes mellitus in systemic lupus erythematosus: systematic review and meta-analysis.Rheumatology (Oxford, England) · 2024Pooled it
- Correction of omega-3 fatty acid deficiency and improvement in disease activity in patients with systemic lupus erythematosus treated with krill oil concentrate: a multicentre, randomised, double-blind, placebo-controlled trial.Lupus science & medicine · 2024Trial
- Long-term association of the triglyceride-glucose index with cardiovascular involvement in systemic lupus erythematosus: a retrospective cohort study.Lupus science & medicine · 2026Article
- Prognostic value of baseline clinical features in SLE: a cluster analysis.Lupus science & medicine · 2026Article
- Immunometabolic remodeling of perivascular adipose tissue in murine lupus: implications for lupus vasculopathy.bioRxiv : the preprint server for biology · 2026Article
- Fronto-cerebellar features associate with cognitive dysfunction in childhood-onset systemic lupus erythematosus.Seminars in arthritis and rheumatism · 2026Article
- Extracorporeal membrane oxygenation for systemic lupus erythematosus: An ELSO registry analysis.Perfusion · 2026Article
- Cardiovascular risk stratification in inflammatory-driven conditions: how far have we come?Frontiers in cardiovascular medicine · 2026Review
- CMV infection in active systemic lupus erythematosus: clinical characteristics, prognosis and treatment outcomes.BMC rheumatology · 2025Article
- Epidemiology of patients with moderate-to-severe SLE in Sweden.Lupus science & medicine · 2025Article
- Understanding Sex Differences in Autoimmune Diseases: Immunologic Mechanisms.International journal of molecular sciences · 2025Review
- Clinical characteristics and risk factors of cardiovascular disease in systemic lupus erythematosus patients.Heart and vessels · 2025Article
- Association between systemic lupus erythematosus and cardiovascular health based on genetic data.Clinical rheumatology · 2025Article
- Rural-urban disparities in hospitalisation for myocardial infarction in systemic lupus erythematosus in the USA.Lupus science & medicine · 2025Article
- Female-bias in systemic lupus erythematosus: How much is the X chromosome to blame?Biology of sex differences · 2024Review
- Damage in a large systemic lupus erythematosus cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) with emphasis on the cardiovascular system: a longitudinal analysis.Lupus science & medicine · 2024Article
- The Expression of Toll-like Receptors (TLR7 and TLR9) in Class III and Class IV of Recently Diagnosed Lupus Nephritis with 12-Month Follow-Up.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo investigate all-cause and cause-specific mortality in SLE patients between two time periods, 1997-2005 and 2006-14.
methodsWe used an administrative health database from the province of British Columbia, Canada to match all incident SLE patients to 10 non-SLE individuals on sex, age and index date. Cohorts were divided into two subgroups, according to diagnosis year: early cohort 1997-2005 and late cohort 2006-14. The outcome was death [all-cause, renal disease, cancer, infection, cardiovascular disease (CVD) and other]. Hazard ratios (HR) and 95% CIs were estimated using univariate and multivariable Cox models.
resultsAmong 6092 SLE patients and 60 920 non-SLE individuals, there were 451 and 1910 deaths, respectively. The fully adjusted all-cause mortality HR (95% CI) in the overall SLE cohort was 1.85 (1.66, 2.06), with no statistically significant improvement between early and late cohorts [1.95 (1.69, 2.26) vs 1.74 (1.49, 2.04)]. There was excess mortality from renal disease [3.04 (2.29, 4.05)], infections [2.74 (2.19, 3.43)] and CVD [2.05 (1.77, 2.38)], but not cancer [1.18 (0.96, 1.46)], in the overall SLE cohort. There was no statistically significant improvement in cause-specific mortality between early and late cohorts for renal disease [3.57 (2.37, 5.36) vs 2.65 (1.78, 3.93)], infection [2.94 (2.17, 3.98) vs 2.54 (1.84, 3.51)] and CVD [1.95 (1.60, 2.38) vs 2.18 (1.76, 2.71)]. There was no increase in cancer-related mortality in either cohort [1.27 (0.96, 1.69) vs 1.10 (0.82, 1.48)].
conclusionThis population-based study demonstrates a persisting mortality gap in all-cause and cause-specific deaths in SLE patients, compared with the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.